Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
British journal of surgery2017Vol. 104(4), pp. 328–336
Citations Over TimeTop 10% of 2017 papers
N. Bird, Mohamed Elmasry, Robert Jones, Eftychia Eirini Psarelli, Julian Dodd, Hafiz Malik, William Greenhalf, N.R. Kitteringham, Paula Ghaneh, John P. Neoptolemos, Daniel H. Palmer
Abstract
Expression of hENT1 is a suitable prognostic biomarker in patients undergoing adjuvant gemcitabine-based chemotherapy.
Related Papers
- → A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer(2013)35 cited
- Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.(2018)
- → EFFORTS TO IMPROVE THE ANTI-TUMOR EFFECT OF GEMCITABINE IN HUMAN PANCREATIC CANCER(2008)
- → A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study(2007)
- Gemcitabine alone versus gemcitabine plus carboplatin in treatment of elderly patients with advanced non-small cell lung cancer(2011)